NitroMed BiDil One Year Ahead Of Schedule Following Positive Study Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is planning for a first quarter 2005 launch after a trial in African American heart failure patients is halted early due to significant survival benefit. Initial positioning will be as an add-on to standard heart failure therapies. NitroMed sees a market opportunity of $1 bil.